[go: up one dir, main page]

EP1169042A4 - Derives de la dibenzo-azepine en tant qu'antagonistes du recepteur alpha v integrine - Google Patents

Derives de la dibenzo-azepine en tant qu'antagonistes du recepteur alpha v integrine

Info

Publication number
EP1169042A4
EP1169042A4 EP00911811A EP00911811A EP1169042A4 EP 1169042 A4 EP1169042 A4 EP 1169042A4 EP 00911811 A EP00911811 A EP 00911811A EP 00911811 A EP00911811 A EP 00911811A EP 1169042 A4 EP1169042 A4 EP 1169042A4
Authority
EP
European Patent Office
Prior art keywords
dibenzo
antagonists
alpha
integrin receptor
azepine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00911811A
Other languages
German (de)
English (en)
Other versions
EP1169042A1 (fr
Inventor
Michael A Patane
Randall C Newton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1169042A1 publication Critical patent/EP1169042A1/fr
Publication of EP1169042A4 publication Critical patent/EP1169042A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00911811A 1999-02-17 2000-02-14 Derives de la dibenzo-azepine en tant qu'antagonistes du recepteur alpha v integrine Withdrawn EP1169042A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12056499P 1999-02-17 1999-02-17
US120564P 1999-02-17
PCT/US2000/003796 WO2000048603A1 (fr) 1999-02-17 2000-02-14 DERIVES DE LA DIBENZO-AZEPINE EN TANT QU'ANTAGONISTES DU RECEPTEUR αV INTEGRINE

Publications (2)

Publication Number Publication Date
EP1169042A1 EP1169042A1 (fr) 2002-01-09
EP1169042A4 true EP1169042A4 (fr) 2003-05-02

Family

ID=22391134

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00911811A Withdrawn EP1169042A4 (fr) 1999-02-17 2000-02-14 Derives de la dibenzo-azepine en tant qu'antagonistes du recepteur alpha v integrine

Country Status (5)

Country Link
EP (1) EP1169042A4 (fr)
JP (1) JP2002537260A (fr)
AU (1) AU750584B2 (fr)
CA (1) CA2362334A1 (fr)
WO (1) WO2000048603A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
US7109191B2 (en) 2001-05-03 2006-09-19 Merck & Co., Inc. Benzazepinone alpha vintegrin receptor antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
DE10242488A1 (de) * 2002-09-13 2004-03-25 Bayer Ag Dibenzoxazeptine
DE102004004928A1 (de) * 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001540A1 (fr) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Antagonistes du recepteur de l'integrine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
EP1027337A4 (fr) * 1997-09-04 2002-04-03 Smithkline Beecham Corp Antagonistes des recepteurs d'integrines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001540A1 (fr) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Antagonistes du recepteur de l'integrine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0048603A1 *

Also Published As

Publication number Publication date
AU750584B2 (en) 2002-07-25
AU3364300A (en) 2000-09-04
JP2002537260A (ja) 2002-11-05
WO2000048603A1 (fr) 2000-08-24
CA2362334A1 (fr) 2000-08-24
EP1169042A1 (fr) 2002-01-09

Similar Documents

Publication Publication Date Title
MA27680A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1
MA26971A1 (fr) Derives de phenylethenyle ou de phenylethinyle en tant qu'antagonistes de recepteur de glutamate
EP1047425A4 (fr) Antagonistes du recepteur de l'integrine
EP1187614A4 (fr) Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
EP1254116A4 (fr) Antagonistes du recepteur de l'integrine alpha v
DZ3443A1 (fr) Derives de 3-aroylindole et leur utilisation en tant qu'agonistes des recepteurs cb2
EP1150965A4 (fr) Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
EP1252162A4 (fr) Antagonistes du recepteur de l'integrine alpha v
MA26933A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.
DE60222647D1 (de) Urea derivate als integrin alpha 4 antagonisten
DK1224175T3 (da) Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
EP1482895A4 (fr) Aminoalkylphosphonates et composes associes utilises en tant qu'agonistes du recepteur edg
EP1501512A4 (fr) Derives de 4-azasteroide utilises comme modulateurs du recepteur de l'androgene
EP1229910A4 (fr) Antagonistes des recepteurs d'integrine
MA25829A1 (fr) Composes de carboxamide et leur utilisation en tant qu'antagonistes de recepteur de cby ii humain
MA26816A1 (fr) Derives d'amino-triazolopyridine
EP1194151A4 (fr) Antagonistes des recepteurs de l'integrine
MA26972A1 (fr) Derives du tetralone en tant qu'agents anti-tumeur
EP1320366A4 (fr) Piperidines substituees en tant qu'agonistes de recepteurs de la melanocortine
DE60023167D1 (de) Pyrazol-derivate als cannabinoidrezeptor-antagonisten
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
EP1482896A4 (fr) Aminoalkylphosphonates et composes associes utilises en tant qu'agonistes du recepteur edg
EP1670483A4 (fr) Derives de 4-azasteroide 17-heterocycliques servant de modulateurs du recepteur d'androgene
DE60007347D1 (de) Isoxazolcarboxamid-derivate als antagonisten des alpha1-adrenergischen rezeptors
EP1171135A4 (fr) Composes 6-azaindole utilises comme antagonistes d'une hormone liberant la gonadotropine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010917

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010917;LT PAYMENT 20010917;LV PAYMENT 20010917;MK PAYMENT 20010917;RO PAYMENT 20010917;SI PAYMENT 20010917

A4 Supplementary search report drawn up and despatched

Effective date: 20030318

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/553 A

Ipc: 7C 07D 413/12 B

Ipc: 7A 61P 19/08 B

Ipc: 7A 61P 9/10 B

Ipc: 7A 61P 35/00 B

17Q First examination report despatched

Effective date: 20030722

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031202